About Sun BioPharma
Sun BioPharma is a publicly listed company based in Ponte Vedra Beach (United States) founded in 2011. Therapeutics for pancreatic cancer and pancreatitis are developed. Sun BioPharma has raised $4.05 million across 10 funding rounds. The company has 4 employees. Its focus areas include Life Sciences, Oncology, Drugs and Pancreatic Cancer. Its legal entity is Sun BioPharma Research, Inc. Its competitors include Tonix Pharma, PanTher Therapeutics and Statera Biopharma; 2 of its 3 listed competitors have raised funding.
Company details
Sun BioPharma develops disruptive therapeutics for diseases of the pancreas, including pancreatitis and pancreatic cancer. Offers SBP-101, a proprietary polyamine for the treatment of pancreatic ductal adenocarcinoma. Products in development stage include SBP-102 and SBP-103 for the treatment of pancreatitis. Has clinical research collaborations with pancreatic disease experts at The Ohio State University, the Fred Hutchinson Cancer Center in Seattle, and other university and research centers.
- Headquarters Ponte Vedra Beach, United States
- Employees 4
- Stage Public
- SectorsHealthcare
- Website sunbiopharma.com
- Social LinkedIn
- Legal Name Sun Biopharma Research, Inc.
- Total Equity Funding$4.05M (USD)
in 10 rounds
- Latest Funding Round$2.5M (USD), Post-IPO
Sep 2019
- Employee Count4
Funding Insights of Sun BioPharma
Sun BioPharma has successfully raised a total of $4.05M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.5 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.05M
- Total Rounds 10
- Last Round Post-IPO — $2.5M
- First Round $548,898
(Mar 2012)
All 10 funding rounds of Sun BioPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $2.5M | Post-IPO | – | – | – |
| Jan 2019 | $1.36M | Post-IPO | – | – | – |
| Feb 2018 | $840,000 | Post-IPO | – | – | – |
| Mar 2017 | $1.5M | Post-IPO | – | – | – |
| Sep 2016 | $2M | Post-IPO | – | – | – |
| Jun 2016 | $1.95M | Post-IPO | – | – | – |
| Sep 2015 | $1.18M | Seed | – | – | – |
| Feb 2014 | $3.1M | Debt – Conventional | – | – | – |
| Jun 2013 | $2.33M | Seed | – | – | – |
| Mar 2012 | $548,898 | Seed | – | – | – |
People of Sun BioPharma
1 people are tracked at Sun BioPharma (1 in leadership); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Paul Herron | Founder, President & CEO | Leadership |
Complete people profiles for Sun BioPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sun BioPharma
4 dated milestones of Sun BioPharma across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Sun BioPharma is founded.
- Funding First funding round of $549K.
- Funding Latest funding round, Post-IPO, of $2.5M.
- IPO Lists on the stock exchange (IPO).
Competitors of Sun BioPharma
Sun BioPharma has 3 listed competitors in our database, 2 of them funded. They include Tonix Pharma, PanTher Therapeutics and Statera Biopharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| panthertx.com | 2014 | Cambridge, United States | $15.35M | 47 | Drug delivery systems for inoperable solid tumors are developed. | |
| staterabiopharma.com | 2003 | Fort Collins, United States | 16 | Immune therapies for cancer and immunological diseases are developed. |
Detailed competitors of Sun BioPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Sun BioPharma (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sun Biopharma
Complete news archive for Sun BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sun BioPharma
Sun BioPharma was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Sun BioPharma is headquartered in Ponte Vedra Beach, United States. It is registered at Ponte Vedra Beach, Florida, United States.
Sun BioPharma is a funded company, having raised a total of $4.05M across 10 funding rounds to date. The company's 1st funding round was a Seed of $548.9K, raised on Mar 2012.
Sun BioPharma has 4 employees.
Sun BioPharma develops disruptive therapeutics for diseases of the pancreas, including pancreatitis and pancreatic cancer. Offers SBP-101, a proprietary polyamine for the treatment of pancreatic ductal adenocarcinoma. Products in development stage include SBP-102 and SBP-103 for the treatment of pancreatitis. Has clinical research collaborations with pancreatic disease experts at The Ohio State University, the Fred Hutchinson Cancer Center in Seattle, and other university and research centers.
Sun BioPharma's top competitors include PanTher Therapeutics, Tonix Pharma and Statera Biopharma.
Sun BioPharma operates through Sun Biopharma Research, Inc..